GlassScriptPhysician profile
Elizabeth Pohl
NPI 1033883723
$4,754.58
in general payments reported to CMS, 2019-2025
45 companies · $841 in 2025
The $841 reported for 2025 was more than what 82% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $396 · 2022: $1,017 · 2023: $1,369 · 2024: $1,130 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,340.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $441.19 | 2021-2023 | Imbruvica, Epkinly |
| Novartis Pharmaceuticals Corporation | $413.36 | 2022-2025 | Kisqali |
| Takeda Pharmaceuticals U.S.A., INC. | $319.57 | 2022-2025 | Fruzaqla, Iclusig, Ninlaro |
| Eisai INC. | $245.76 | 2022-2025 | |
| Astellas Pharma US INC | $211.44 | 2021-2025 | Vyloy, Xospata |
| Abbvie INC. | $211.04 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $208.00 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Lilly USA, LLC | $205.86 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Ipsen Biopharmaceuticals, INC | $174.18 | 2023-2025 | Onivyde, Tazverik |
| Seagen INC. | $163.92 | 2022-2023 | Tukysa, Padcev, Tivdak |
| Astrazeneca Pharmaceuticals LP | $161.49 | 2023-2024 | Tagrisso, Calquence, Lynparza |
| Genentech USA, INC. | $159.05 | 2022-2023 | Tecentriq |
| Incyte Corporation | $158.86 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Janssen Biotech, INC. | $150.09 | 2022-2024 | Tecvayli, Darzalex, Erleada |
| Amgen INC. | $131.92 | 2022-2023 | Blincyto |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $122.59 | 2022-2024 | |
| Daiichi Sankyo INC. | $120.71 | 2022-2025 | Enhertu, Injectafer |
| Amag Pharmaceuticals, INC. | $118.15 | 2021 | |
| Genzyme Corporation | $110.95 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $72.75 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.45 | 2023-2024 | |
| Beone Medicines USA, INC. | $58.09 | 2025 | Brukinsa |
| Exelixis INC. | $54.75 | 2022-2024 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $54.27 | 2022-2023 | Tavalisse, Rezlidhia |
| Beigene USA, INC. | $52.33 | 2024-2025 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $51.76 | 2024-2025 | Qinlock |
| Kyowa Kirin, INC. | $48.06 | 2023-2025 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.65 | 2022-2023 | Gilotrif |
| Stemline Therapeutics INC. | $40.74 | 2023-2024 | Elzonris, Orserdu |
| Alexion Pharmaceuticals, INC. | $40.49 | 2022-2023 | Ultomiris |
| Gilead Sciences, INC. | $39.25 | 2024 | Trodelvy |
| Caris Mpi, INC. | $33.19 | 2025 | Mi Cancer Seek |
| Sobi, INC | $30.81 | 2024 | |
| Emd Serono, INC. | $30.28 | 2023 | Tepmetko |
| Tersera Therapeutics LLC | $28.16 | 2025 | Zoladex |
| Amneal Pharmaceuticals LLC | $25.10 | 2023 | Avastin |
| Alnylam Pharmaceuticals INC. | $23.30 | 2022 | |
| Celgene Corporation | $22.71 | 2025 | Reblozyl |
| Springworks Therapeutics, INC. | $20.45 | 2024 | Ogsiveo |
| Pharmaessentia USA Corporation | $16.30 | 2024 | Besremi |
| Sumitomo Pharma America, INC. | $15.56 | 2023 | Orgovyx |
| Myovant Sciences INC. | $14.54 | 2022 | |
| Karyopharm Therapeutics INC. | $13.96 | 2024 | Xpovio |
| Aveo Pharmaceuticals, INC. | $13.79 | 2022 | |
| Morphosys, US INC. | $13.71 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Pohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.